Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study

Conditions:   Squamous Cell Carcinoma, Head And Neck;   Squamous Cell Carcinoma Mouth;   Squamous Cell Carcinoma of the Oral Cavity
Interventions:   Drug: Sitravatinib;   Biological: Nivolumab
Sponsors:   University Health Network, Toronto;   Mirati Therapeutics Inc.
Not yet recruiting

https://ift.tt/2MGV1ky